New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:20 EDTVRTXVertex focused on programs in CF, hepatitis C and autoimmune diseases in 2013
Vertex’s key strategies and business priorities include: Focusing investment on key development programs for: Cystic Fibrosis, CF: Vertex’s CF strategy is to provide benefit to as many CF patients as possible. Hepatitis C: Vertex’s strategy in hepatitis C is to develop new all-oral treatment regimens of 12 weeks or less in duration with a goal of providing a high viral cure rate and improved tolerability. In 2013, Autoimmune Diseases: Vertex’s strategy in autoimmune diseases is to maximize the value of VX-509 across multiple autoimmune diseases globally. The company will evaluate collaborative opportunities that provide funding and capabilities to broaden and accelerate global development of VX-509. Autoimmune Diseases: Maximizing revenues and cash flow from the appropriate use of INCIVEK®(telaprevir) and KALYDECO in the U.S. and Canada and from the growth of KALYDECO in Europe and other countries 4. Maintaining financial strength to support future growth and shareholder returns.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
09:06 EDTVRTXVertex names David Altshuler as Chief Scientific Officer
Subscribe for More Information
December 12, 2014
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use